Vantage Point

Our latest thinking on biopharmaceutical development and commercialization.

Michelle Krausz
Latest thinking
How education and support programs help patients with cardiovascular disease.

Quintiles Blog

Fresh ideas and insights from our experts around the globe


Topics to Explore


Advances in genomics and information technology are ushering in a new era for oncology drug development, but biopharmaceutical companies must move the conversation from cost to value.


As the prevalence of diabetes continues to increase globally, and the market for new therapies grows increasingly crowded, it's more important than ever to match the right drug to the right patient.

Data & Technology

To turn data into insights, upgraded IT systems are essential. Outdated systems lead to significant costs – in terms of time, frustration and an increased risk of errors. Integrated IT systems are a crucial component in reducing manual processes, resulting in fewer errors, faster processes, far less frustration and ultimately lowering your costs. Benefit from more insightful data analysis, which can lead to groundbreaking discoveries.

  • White paper: GMP - data integrityData integrity problems on the rise: Risks, causes and practical solutions
  • Blog post: Could transparency improve Pharma's image?
  • Blog post: Integrated Multi-Channel Engagement: A new model for pharma marketing
  • Blog post: Karen Knecht - What Should We Be Doing With EHR Data?

Evidence & Value

Healthcare costs are climbing, regulators around the globe are requiring more information, and both providers and payers have higher expectations for a medical treatment’s proof of value before prescribing or paying for those treatments.

Rare Diseases

3+ years looking for treatment

Although regulatory incentives and the designation of “orphan” products have stimulated commercial research for rare diseases, their low prevalence, high complexity and predominance in children create significant barriers. Providers and patients are clamoring for treatment access and improved outcomes, but increasingly payers are making hard choices about reimbursing these therapies.

  • Blog post: Lupus Trials are on the Rise
  • Blog post: NGS Improves Feasibility of Clinical Trials for Rare Disease Populations
  • Blog post: Every Patient Counts: How to Make the Most of Rare Disease Registries
  • Blog post: Kids Talk on Rare Disease Day
  • Podcast: Kathryn Starzyk on patient registries in rare disease research
  • Podcast: Cindy Jackson on rare disease research in pediatric populations
  • Blog post: Bringing Orphan Drugs to Market


Biosimilar development and commercialization is a uniquely difficult endeavor requiring precise, stepwise planning to ensure timely regulatory approval and optimal market access. 

Peer-Reviewed Publications
The Influence of Ultrasound Measurement Techniques on the Age-Related Differences in Achilles Tendon Size.
Exp Gerontol. 2016 Jan 28. pii: S0531-5565(16)30015-8. doi: 10.1016/j.exger.2016.01.015. [Epub ahead of print]
Read more
Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies.
Drugs R D. 2016 Jan 9. [Epub ahead of print]
Read more
Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma.
Leuk Lymphoma. 2016 Jan 12:1-14. [Epub ahead of print]
Read more
Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
Drugs R D. 2016 Jan 6. [Epub ahead of print]
Read more
Impact of treatment strategies for open angle glaucoma on intraocular pressure: the RiGOR study.
J Comp Eff Res. 2016 Jan;5(1):87-98. doi: 10.2217/cer.15.58. Epub 2015 Dec 22.
Read more